Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02)
暂无分享,去创建一个
A. Wu | Xiaoyan Zhang | Lin Wang | Wei-hu Wang | T. Zhan | Zhong-Wu Li | Ying-Shi Sun | Peng-ju Chen | T. Sun | Yongheng Li | Jun Zhao | Jia-hua Leng | Yi-fan Peng | Y. Cai | Yun-feng Yao | Yi-fan Peng | A. Wu | Wei-Hu Wang | Yong Cai
[1] Chen Hu,et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Friede,et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. , 2021, JAMA oncology.
[3] Gong Chen,et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. , 2021, The oncologist.
[4] T. Conroy,et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.
[5] H. Putter,et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.
[6] F. Petrelli,et al. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. , 2020, Annals of surgery.
[7] D. Winter,et al. Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer , 2019, The British journal of surgery.
[8] T. Friede,et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] I. Petkovska,et al. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy , 2019, JAMA oncology.
[10] J. Gama-Rodrigues,et al. Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think! , 2019, Diseases of the colon and rectum.
[11] Matthew P. Goetz,et al. NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .
[12] Zongguang Zhou,et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] C. Maurer,et al. Oncological outcome after MRI‐based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial , 2018, The British journal of surgery.
[14] I. Edhemovic,et al. Induction Chemotherapy, Chemoradiotherapy and Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer - Long-term Results of Phase II OIGIT-01 Trial , 2018, Radiology and oncology.
[15] Ahmed Kamel,et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[16] G. Beets,et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study , 2018, The Lancet.
[17] J. Ji,et al. Pattern and Management of Recurrence of Mid‐Low Rectal Cancer After Neoadjuvant Intensity‐Modulated Radiotherapy: Single‐Center Results of 687 Cases , 2018, Clinical colorectal cancer.
[18] R. Perez,et al. Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis , 2018, Annals of surgery.
[19] Lijun Shen,et al. Predictive value of MRI-detected extramural vascular invasion in stage T3 rectal cancer patients before neoadjuvant chemoradiation. , 2018, Diagnostic and interventional radiology.
[20] C. Montagut,et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] T. Hothorn,et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.
[22] J. Gu,et al. Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy With Concurrent Capecitabine for Locally Advanced Rectal Cancer , 2015, Diseases of the colon and rectum.
[23] M. Lacouture,et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. , 2012, Journal of the American Academy of Dermatology.
[24] Torsten Hothorn,et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. , 2012, The Lancet. Oncology.
[25] L. Boni,et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Hein Putter,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.
[27] D. Tait,et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. , 2010, The Lancet. Oncology.
[28] S. Polo,et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer d , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Makuuchi,et al. The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience , 2009, Annals of surgery.
[30] Laurence Collette,et al. Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.
[31] H. Putter,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. , 2001, The New England journal of medicine.